CUSIP: 87410C104
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,432,226
-
Share change
-
+1,237,364
-
Total reported value
-
$77,084,574
-
Price per share
-
$2.81
-
Number of holders
-
48
-
Value change
-
+$3,239,152
-
Number of buys
-
17
-
Number of sells
-
30
Quarterly Holders Quick Answers
What is CUSIP 87410C104?
CUSIP 87410C104 identifies TALS - TALARIS THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 87410C104:
Institutional Holders of TALARIS THERAPEUTICS INC - COM (TALS) as of Q3 2023
As of 30 Sep 2023,
TALARIS THERAPEUTICS INC - COM (TALS) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,432,226 shares.
The largest 10 holders included
Blackstone Inc., Nantahala Capital Management, LLC, Qiming U.S. Ventures Management, LLC, RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Balyasny Asset Management L.P., VANGUARD GROUP INC, GREAT POINT PARTNERS LLC, Artal Group S.A., and QVT Financial LP.
This page lists
48
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.